Entering text into the input field will update the search result below

New Issue: Invacare Corp. (IVC) Convertible Senior Notes Due 2021

Feb. 18, 2016 11:31 AM ETIVCRQ
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New Issue: Invacare Corp. (IVC) Convertible Senior Notes due 2021

Introduction

Invacare last visited the convertible market in 2007. In that year, the company raised $135 million via the issuance of 4.125% convertible senior subordinated bonds due 2027. Only $13.5 million of that issue remains outstanding, the vast majority having been retired through a combination of non-core asset dispositions and other actions. In this latest transaction, the company is bringing a $130 million convertible senior note issue. IVC is a global leader in the manufacture and distribution of durable medical equipment for non-acute care selling to home medical equipment distributors, rehabilitation facilities, and long-term care providers in over 100 countries worldwide. The deal is taking the form of a "happy meal", with a significant percentage of the buyers apparently shorting stock to the company and underwriters.

More on the Bond …

Based on a price-talk midpoint believed to be 4.75% up 30% on a five-year bullet, our initial HOCS slash line measures 55 Overall / 62 Growth / 41 Safety, a fairly poor score for a new deal. The overall and growth scores reflect the company's declining revenues and operating losses. At $16.84, IVC's stock is trading towards the bottom of its 52-week range ($13.99-23.54). Moreover, the company's market capitalization is a skinny $548 million. This fails to meet our "five times deal size" rule of thumb, albeit by a narrow margin. One of several cautionary signals. That helps explain why the optics are so appealing, the bond's saving grace.

More on the Credit …

IVC boasts several positive attributes. A large addressable market, strong channel relationships, a clinically relevant portfolio and the ability to regularly deliver innovative new products. In addition, market diversity from country and health care payor perspectives and a broad base of products and relevant therapies ought to support margins for the foreseeable future. Unfortunately, revenues have been under pressure the past several years. (5-Year CAGR = -4%) What's behind the top line erosion? Reimbursement reductions relating to the roll-out of national competitive bidding have taken a toll. Furthermore, IVC continues to operate under a consent decree with the U.S. FDA centered on the manufacture of (motorized) wheelchairs. A meaningful headwind as well. Finally, currency pressures continue to weigh on revenues as well. A turnaround and cost cutting effort is underway in an effort to combat these pressures. A little revenue growth would go a long way.

Summary Financials

(LTM Pro Forma)

($MM)

Revenues

1,142

EBITDA

17

Cash

60

Total Debt

197

Market Capitalization

548

Sources: Company filings and Hillside Advisors

Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You